Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...

W-2 forms should have arrived in mailboxes and inboxes by Jan. 31. Here's why you need that form for the 2025 tax season and what to do if you haven't gotten yours yet. Macy Meyer is a North ...

That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...

Vertex is continuing to engage with experienced hospitals throughout England to establish a network of independently operated authorized treatment centers (ATCs). SCD is a debilitating, progressive, ...

Vertex Pharmaceuticals (Nasdaq ... SCD patients report health-related quality of life scores well below the general population and significant health care resource utilization.

The journey was fittingly excruciating. Pain, as Vertex Pharmaceuticals found out, is wildly complex. It starts simple enough, with a sliced hand or burned finger or broken bone. But it convolutes ...

Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...

Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of $460. Published first on TheFly – the ultimate source ...

Analysts project ongoing solid performance from the CF business. BMO Capital Markets estimates Vertex will generate revenues of $11,573 million in 2025, with earnings per share reaching $18.05 ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...